<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03602261</url>
  </required_header>
  <id_info>
    <org_study_id>CTAP101-CL-2010</org_study_id>
    <nct_id>NCT03602261</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI</brief_title>
  <official_title>A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of CTAP101 (Calcifediol) Extended-Release Capsules to Treat Secondary Hyperparathyroidism in Subjects With Vitamin D Insufficiency and Chronic Kidney Disease Requiring Regular Hemodialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OPKO Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OPKO Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-Center, Randomized, Two-Cohort Phase 2 Study to Evaluate the Safety, Efficacy,&#xD;
      Pharmacokinetics and Pharmacodynamics of CTAP101 (calcifediol) Extended-Release Capsules to&#xD;
      Treat Secondary Hyperparathyroidism in Subjects with Vitamin D Insufficiency and Chronic&#xD;
      Kidney Disease Requiring Regular Hemodialysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mean plasma intact parathyroid hormone (iPTH)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change of at least 30% from pre-treatment baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Treatment-Emergent Adverse Events as assessed by CTCAE version 5.0</measure>
    <time_frame>32 weeks</time_frame>
    <description>Detailed information collected for each TEAE will include: AE number, a description of the event, start date, end date or ongoing as of date, outcome, therapy for event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>74 weeks</time_frame>
    <description>Maximum serum concentration of Calcifediol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase mean serum total 25-hydroxyvitamin D</measure>
    <time_frame>26 weeks</time_frame>
    <description>Increase to ≥30 ng/mL</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Secondary Hyperparathyroidism Due to Renal Causes</condition>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Stage 5 Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 300mcg/weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 600mcg/weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsules weekly</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Capsules/weekly for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcifediol Oral Capsule</intervention_name>
    <description>Capsule, weekly</description>
    <arm_group_label>CTAP101 Capsules 300mcg/weekly</arm_group_label>
    <arm_group_label>CTAP101 Capsules 600mcg/weekly</arm_group_label>
    <arm_group_label>CTAP101 Capsules 900mcg/weekly</arm_group_label>
    <other_name>CTAP101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Capsule, weekly</description>
    <arm_group_label>Placebo Capsules weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each subject must meet the following criteria to be enrolled into the two cohorts of this&#xD;
        study:&#xD;
&#xD;
          1. Be at least 18 years of age.&#xD;
&#xD;
          2. Be diagnosed with CKD requiring in-center HD tiw for the preceding 6 months, as&#xD;
             confirmed by medical history.&#xD;
&#xD;
          3. Be without any disease state or physical condition that might impair evaluation of&#xD;
             safety or which, in the investigator's opinion, would interfere with study&#xD;
             participation, including:&#xD;
&#xD;
               1. Serum albumin ≤ 3.0 g/dL; and,&#xD;
&#xD;
               2. Serum transaminase (alanine transaminase [ALT], glutamic pyruvic transaminase&#xD;
                  [SGPT], aspartate aminotransferase [AST] or glutamic oxaloacetic transaminase&#xD;
                  [SGOT]) &gt; 2.5 times the upper limit of normal at screening.&#xD;
&#xD;
          4. Be receiving calcimimetic therapy (either etelcalcetide or cinacalcet) and/or&#xD;
             calcitriol or other 1α-hydroxylated vitamin D analog (paricalcitol or doxercalciferol)&#xD;
             for at least 1 month at the time of screening for enrollment. At least 50% of enrolled&#xD;
             subjects will have been receiving calcimimetic therapy.&#xD;
&#xD;
          5. Exhibit during the initial screening visit:&#xD;
&#xD;
               1. Plasma iPTH ≥150 pg/mL and &lt;600 pg/mL if receiving etelcalcetide, cinacalcet,&#xD;
                  calcitriol or other 1α-hydroxylated vitamin D analog (paricalcitol or&#xD;
                  doxercalciferol); or&#xD;
&#xD;
               2. Plasma iPTH ≥300 pg/mL and &lt;900 pg/mL if not receiving etelcalcetide, cinacalcet,&#xD;
                  calcitriol or other 1α-hydroxylated vitamin D analog; and,&#xD;
&#xD;
               3. Serum total 25-hydroxyvitamin D &lt;30 ng/mL if not receiving vitamin D&#xD;
                  supplementation.&#xD;
&#xD;
          6. When otherwise confirmed eligible at Visit 1, must forgo any further treatment with&#xD;
             etelcalcetide and cinacalcet for the duration of the study and undergo an 8-week&#xD;
             washout period.&#xD;
&#xD;
          7. When otherwise confirmed eligible at Visit 1, must forgo any further treatment with&#xD;
             calcitriol or other 1α-hydroxylated vitamin D analogs or vitamin D supplements for the&#xD;
             duration of the study and undergo an 8-week washout period.&#xD;
&#xD;
          8. Exhibit after the 8-week washout period (if required due to prior use of&#xD;
             etelcalcetide, cinacalcet, calcitriol or other 1α-hydroxylated vitamin D analogs, or&#xD;
             vitamin D supplementation):&#xD;
&#xD;
             Cohort 1:&#xD;
&#xD;
               1. Plasma iPTH increased by at least 50%; and,&#xD;
&#xD;
               2. Plasma iPTH ≥300 pg/mL and &lt;1,200 pg/mL; or,&#xD;
&#xD;
             Cohort 2:&#xD;
&#xD;
             a. Plasma iPTH ≥300 pg/mL and &lt;1,200 pg/mL (approximately half of the subjects will be&#xD;
             enrolled in each of these two iPTH strata: ≥300 to &lt;600 and ≥600 to &lt;1,200 pg/mL); and&#xD;
&#xD;
             Cohorts 1 and 2:&#xD;
&#xD;
               1. Corrected serum calcium &lt;9.8 mg/dL;&#xD;
&#xD;
               2. Serum total 25-hydroxyvitamin D &lt;30 ng/mL; and,&#xD;
&#xD;
               3. Serum phosphorus &lt;6.5 mg/dL.&#xD;
&#xD;
          9. When otherwise confirmed eligible at Visit 1, if taking more than 1,000 mg per day of&#xD;
             elemental calcium, reduce calcium use (to ≤1,000 mg per day) and/or use non-calcium&#xD;
             based phosphate binder therapies (as needed) for the duration of the study.&#xD;
&#xD;
         10. When otherwise confirmed eligible at Visit 1, if taking bone metabolism therapies that&#xD;
             may interfere with study endpoints, must discontinue use of these agents for the&#xD;
             duration of the study.&#xD;
&#xD;
         11. Willing and able to comply with study instructions and commit to all clinic visits for&#xD;
             the duration of the study.&#xD;
&#xD;
         12. Female subjects of childbearing potential must be neither pregnant nor lactating and&#xD;
             must have a negative serum beta-human chorionic gonadotropin (b-hCG) pregnancy test at&#xD;
             the first screening visit and at other scheduled times.&#xD;
&#xD;
         13. All female subjects of childbearing potential and male subjects with female partners&#xD;
             of childbearing potential must agree to use effective contraception (eg, implants,&#xD;
             injectables, combined oral contraceptives, intrauterine device, sexual abstinence,&#xD;
             vasectomy or vasectomized partner) for the duration of the study.&#xD;
&#xD;
         14. Be able to read, understand and sign the subject Informed Consent Form (ICF) or have a&#xD;
             legal representative sign the ICF.&#xD;
&#xD;
        4.3 Exclusion Criteria&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Scheduled kidney transplant or parathyroidectomy.&#xD;
&#xD;
          2. History (prior 2 months) of corrected serum calcium ≥9.8 mg/dL or serum phosphorus&#xD;
&#xD;
             ≥6.5 mg/dL if not receiving calcitriol or other 1α-hydroxylated vitamin D analog.&#xD;
&#xD;
          3. Receipt of bisphosphonate therapy or other bone modifying treatment (eg, denosumab)&#xD;
             within 6 months prior to enrollment.&#xD;
&#xD;
          4. Known previous or concomitant serious illness or medical condition, such as&#xD;
             malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic&#xD;
             disease, intestinal malabsorption disorder, hepatitis or cardiovascular event that in&#xD;
             the opinion of the investigator may worsen or reduce life expectancy, and/or interfere&#xD;
             with participation in the study.&#xD;
&#xD;
          5. History of neurological/psychiatric disorder, including psychotic disorder or&#xD;
             dementia, or any reason which, in the opinion of the investigator makes adherence to a&#xD;
             treatment or follow-up schedule unlikely.&#xD;
&#xD;
          6. Known or suspected hypersensitivity to any of the constituents of the study drugs.&#xD;
&#xD;
          7. Currently participating in, or has participated in, an interventional/investigational&#xD;
             study within 30 days prior to study screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AKDHC Medical Research Services</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Services</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WCCT Global, Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacienda Dialysis Center</name>
      <address>
        <city>Hacienda Heights</city>
        <state>California</state>
        <zip>91745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research CKD/Dialysis &amp; Transplant Division</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Quest Dialysis Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ontario Dialysis Center</name>
      <address>
        <city>Ontario</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North America Research Institute, Inc.</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurel Canyon Dialysis, LLC</name>
      <address>
        <city>Sun Valley</city>
        <state>California</state>
        <zip>91352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research by Design, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60643</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore University Health</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal and Transplant Associates of New England</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest MS Nephrology</name>
      <address>
        <city>McComb</city>
        <state>Mississippi</state>
        <zip>39601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Houston Research LTD</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidney &amp; Hypertension Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

